drugset

drugset / Trial / NCT02133339

Single Ascending Dose Study of TRN-157 in Healthy Subjects

NCT02133339 ↗

Phase 1 Completed 30 enrolled Theron Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This single ascending dose study is to determine and evaluate the safety and tolerability of TRN-157 in approximately 40 healthy subjects.

Timeline

Start: 2014-05
Primary completion: 2014-08
Completion: 2014-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TRN-157	Unknown	—	Inhaled

Indications